Ranibizumab SPC Cut By Nearly Two Years In UK
Filing Error Slices Nearly Two Years Off Roche’s UK Lucentis Protection
A ruling by the High Court has cut almost two years from UK SPC protection for Roche's Lucentis ranibizumab brand, potentially offering biosimilar competitors the change to jump into the market early.
You may also be interested in...
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
Stada and Xbrane Biopharma have struck a co-development deal covering the Swedish firm’s Xlucane (ranibizumab) biosimilar, a proposed rival to Genentech’s Lucentis, with a worldwide scope.